Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Test How Well Different Doses of BI 1815368 Are Tolerated by Healthy Men

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1815368
Drug: Matching placebo

First Posted Date: 2023-05-15

Last Posted Date: 2024-11-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 59

Registration Number: NCT05857878

Locations: 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium

A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome

Phase 2

Active, not recruiting

Conditions: Netherton Syndrome

Interventions: Drug: Spesolimab - solution for infusion
Drug: Placebo matching to spesolimab - solution for infusion
Drug: Spesolimab - solution for injection
Drug: Placebo matching to spesolimab - solution for injection

First Posted Date: 2023-05-12

Last Posted Date: 2025-05-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 43

Registration Number: NCT05856526

Locations: 🇨🇳
Beijing Children's Hospital, Capital Medical University, Beijing, China
🇺🇸
Mission Dermatology Center, Rancho Santa Margarita, California, United States
🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States

and more 24 locations

Developing a Screening Tool for Interstitial Lung Disease in People With Rheumatoid Arthritis Using Risk Factors

Active, not recruiting

Conditions: Arthritis, Rheumatoid
Lung Diseases, Interstitial

First Posted Date: 2023-05-11

Last Posted Date: 2025-04-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1203

Registration Number: NCT05855109

Locations: 🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain
🇪🇸
Hospital General Universitario De Valencia, Valencia, Spain
🇪🇸
Hospital Do Meixoeiro, Vigo, Spain

and more 25 locations

Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine

Phase 2

Active, not recruiting

Conditions: Bronchiectasis

Interventions: Drug: BI 1291583
Drug: Placebo matching BI 1291583

First Posted Date: 2023-05-06

Last Posted Date: 2025-04-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 269

Registration Number: NCT05846230

Locations: 🇧🇬
Medical Center "Zdrave-1", Kozloduy, Bulgaria
🇧🇬
Medica Center Hera - Montana Branch, Montana, Bulgaria
🇧🇬
Medical Center ReSpiro Ltd, Razgrad, Bulgaria

and more 99 locations

A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer

Phase 1

Terminated

Conditions: Solid Tumors

Interventions: Drug: BI 1821736

First Posted Date: 2023-05-03

Last Posted Date: 2025-05-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 10

Registration Number: NCT05839600

Locations: 🇸🇪
Karolinska Universitetssjukhuset Stockholm, Stockholm, Sweden
🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸
NEXT Oncology-San Antonio-65273, San Antonio, Texas, United States

and more 4 locations

A Study in Healthy Men to Test How BI 1291583 is Processed in the Body

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1291583 mixed with [C-14] BI 1291583

First Posted Date: 2023-04-27

Last Posted Date: 2023-07-12

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 8

Registration Number: NCT05833035

Locations: 🇳🇱
ICON, Groningen, Netherlands

A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1810631 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1810631
Drug: Itraconazole

First Posted Date: 2023-04-27

Last Posted Date: 2024-10-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT05833139

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

Phase 2

Completed

Conditions: Hidradenitis Suppurativa

Interventions: Drug: Spesolimab Formulation 1
Drug: Placebo matching Spesolimab Formulation 1
Drug: Spesolimab Formulation 2
Drug: Placebo matching Spesolimab Formulation 2

First Posted Date: 2023-04-19

Last Posted Date: 2025-05-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 209

Registration Number: NCT05819398

Locations: 🇵🇱
Frederic Chopin University Hospital No. 1 in Rzeszow, Rzeszow, Poland
🇵🇱
High-Med Specialist Clinic, Warsaw, Warsaw, Poland
🇵🇱
National Medical Institute MSWiA, Warsaw, Poland

and more 155 locations

Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) Epidemiology Non-interventional Study (NIS)

Not yet recruiting

Conditions: Lung Diseases, Interstitial

First Posted Date: 2023-04-19

Last Posted Date: 2025-04-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 312

Registration Number: NCT05819385

Dose Reduction and Discontinuation With Anti-Fibrotic Medications

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Nintedanib
Drug: Pirfenidone

First Posted Date: 2023-03-22

Last Posted Date: 2023-09-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 2778

Registration Number: NCT05779007

Locations: 🇺🇸
Boehringer Ingelheim, Ridgefield, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy